Literature DB >> 4019037

Glaucoma in China.

T H Pei.   

Abstract

The motivation for this paper is that, having come from China, a country which had closed herself to the outside world for three decades, I thought it might be interesting to compare glaucoma in the two countries. Since I am from only a municipal hospital of a small city Hangzhow (a sister city of Boston), whatever I say can only be accepted as personal view points. Presently I have this wonderful opportunity to be a research fellow at the world wide famous Massachusetts Eye & Ear Infirmary, which is affiliated with Harvard Medical School. The comparison therefore may not be exactly appropriate but may help to see where my country stands, what we have, what we lack and what goals to strive for to better the health of China. There may be some confusing terms in this paper such as 'Liberation', 'Cultural Revolution', etc. Table 1 may help give a clearer conception.

Entities:  

Mesh:

Year:  1985        PMID: 4019037     DOI: 10.1007/bf00136462

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  5 in total

1.  [Peripheral iridectomy: its prophylactic significance in angle-closure glaucoma (author's transl)].

Authors:  X C Ji
Journal:  Zhonghua Yan Ke Za Zhi       Date:  1979-05

2.  [Prevalence of narrow-angled eye in refraction cases].

Authors:  H Nose; Y Kitazawa; I Iino; C Nakamura; Y Nakamura
Journal:  Nihon Ganka Kiyo       Date:  1971-11

3.  Primary glaucoma in Greenland (Umanaq district). I. Introduction. The normal intraocular pressure.

Authors:  P H Alsbirk
Journal:  Acta Ophthalmol (Copenh)       Date:  1970

4.  [Prevention of blindness in rural areas of north China during the past 30 years (author's transl)].

Authors:  Q Dang
Journal:  Zhonghua Yan Ke Za Zhi       Date:  1980-11

5.  Why do some people go blind from glaucoma?

Authors:  W M Grant; J F Burke
Journal:  Ophthalmology       Date:  1982-09       Impact factor: 12.079

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.